Therapeutic efficacy of charcoal hemoperfusion in @entity1 with acute severe XXXX .

@entity1 @entity28962 @entity935 @entity772 @entity4968 @entity3897 @entity1662 @entity912
AIM: To assess the efficacy of hemoperfusion (HP) in the treatment of the @entity1 with acute severe @entity28962 ( @entity28962 ) @entity4968 . METHODS: One hundred and eight @entity1 with acute severe @entity28962 @entity4968 in the two teaching hospitals were enrolled. Sixty-seven @entity1 were treated with HP (HP group) and forty-one @entity1 accepted traditional treatment only as the control. Serum concentration of @entity28962 was determined by gas chromatography. RESULTS: The duration of @entity772 , @entity1662 , ICU stay, and mechanical ventilation was significantly shorter in the HP group than that in the control. The cumulative dosages (mg) of @entity3897 required either in the first 24 h on admission (442+/-436 vs 899+/-485 in the control, P<0.01) or within the hospital (568+/-574 vs 1228+/-982 in the control, P<0.01) were markedly reduced in the HP @entity1 . The lower incidence of mechanical ventilation required (13.4 % vs 36.6 % P<0.01), respiratory muscular @entity912 (4.5 % vs 17.1 %, P<0.05) and the lower mortality of death (7.5 % vs 34.1 %, P<0.01) were observed in the HP group. HP could accelerate the recovery of suppressed cholinesterase activity. After the procedure, the @entity28962 level was decreased from (11+/-4) to (7+/-3) mg/L in parallel with a decline in APACHE II Score or @entity935 dose and a rise in Glasgow @entity772 Scale (P<0.05). In addition, the mean values of peak clearance and reduction rate were (87+/-17) mL/min and 44 %+/-11 %, respectively. CONCLUSION: The rapid fall in blood @entity28962 level and the dramatic clinical response suggest that HP is effective in the treatment of acute severe @entity28962 @entity4968 .
